entertainment -WSS

entertainment

author：knowledge 2025-09-06 08:39:33 - browse：26718

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Drug companies' payments and gifts affect physicians' prescribing

explore

WSS

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

AI can decode, harness the power of the humane immune system

FDA authorizes Novavax’s updated Covid

FDA authorizes Novavax’s updated Covid

Scientific mystery highlights the blind spots in genomics databases

Trial using CRISPR to edit HIV out of cells disappoints

Wikipedia

entertainment

explore

Alkermes shareholders re

Medicare Advantage 2025 payments will dip, Biden administration says

Medical leaders decry Supreme Court decision on affirmative action

Trial using CRISPR to edit HIV out of cells disappoints

As demand for Covid shots wanes, Moderna seeks its next success

First Opinion on colorectal cancer screening: letter and response

Trump demands the U.S. pay no more for drugs than other countries … again

Bird flu reported in person exposed to presumably infected cattle

Jerome Adams on the need for new antivirals for Covid

Why Charlie Gard's case is so disturbing to Americans

hotspot

Trial using CRISPR to edit HIV out of cells disappoints

Senate panel eyes new effort on drug shortages

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Researchers test human milk's ability to repair gut microbiome

Medicare Advantage 2025 payments will dip, Biden administration says

Trial using CRISPR to edit HIV out of cells disappoints

entertainment

leisure time

explore

hotspot